Ornithine Transcarbamylase Deficiency Drugs Market
The report also provides a detailed analysis of the current Ornithine Transcarbamylase Deficiency marketed drugs and late-stage pipeline drugs. The escalating prevalence of mutations in the OTC gene that can lead to a deficiency or absence of the OTC enzyme, essential for processing ammonia, is primarily driving the market.